Review
Open access
Aug 2026
CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates
A therapeutic-window strategy in which a defined exposure is assessed for a measurable immune change before treatment is escalated is supported, in which a defined exposure is assessed for a measurable immune change before treatment is escalated.
C. Zheng, Yue Pan, Danni Zheng et al.
· Frontiers in Immunology · 0 citations